B
47.76
0.39 (0.81%)
| Previous Close | 47.37 |
| Open | 47.78 |
| Volume | 1,024,611 |
| Avg. Volume (3M) | 2,834,454 |
| Market Cap | 9,067,766,784 |
| Price / Sales | 41.19 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 98.93%) | Buy |
| Median | 69.00 (44.49%) | |
| Low | 54.00 (B of A Securities, 13.08%) | Buy |
| Average | 69.67 (45.89%) | |
| Total | 12 Buy | |
| Avg. Price @ Call | 47.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Sep 2025 | 70.00 (46.58%) | Buy | 51.47 |
| 03 Sep 2025 | 70.00 (46.58%) | Buy | 51.84 | |
| UBS | 12 Sep 2025 | 82.00 (71.71%) | Buy | 51.21 |
| JP Morgan | 03 Sep 2025 | 70.00 (46.58%) | Buy | 51.84 |
| Oppenheimer | 06 Aug 2025 | 61.00 (27.74%) | Buy | 44.81 |
| 09 Jul 2025 | 60.00 (25.64%) | Buy | 45.98 | |
| Scotiabank | 06 Aug 2025 | 57.00 (19.36%) | Buy | 44.81 |
| Cantor Fitzgerald | 29 Jul 2025 | 95.00 (98.93%) | Buy | 46.32 |
| Truist Securities | 21 Jul 2025 | 66.00 (38.21%) | Buy | 45.90 |
| Jefferies | 14 Jul 2025 | 70.00 (46.58%) | Buy | 47.69 |
| Piper Sandler | 14 Jul 2025 | 68.00 (42.39%) | Buy | 47.69 |
| Citigroup | 11 Jul 2025 | 67.00 (40.30%) | Buy | 46.47 |
| Wells Fargo | 30 Jun 2025 | 76.00 (59.15%) | Buy | 43.18 |
| B of A Securities | 25 Jun 2025 | 54.00 (13.08%) | Buy | 44.38 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KUMAR NEIL | - | 52.61 | -80,000 | -4,208,400 |
| MCCORMICK FRANK | - | 53.38 | -74,000 | -3,950,120 |
| Aggregate Net Quantity | -154,000 | |||
| Aggregate Net Value ($) | -8,158,520 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 52.86 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KUMAR NEIL | Officer | 05 Sep 2025 | Automatic sell (-) | 40,000 | 53.38 | 2,135,200 |
| MCCORMICK FRANK | Director | 05 Sep 2025 | Sell (-) | 74,000 | 53.38 | 3,950,120 |
| MCCORMICK FRANK | Director | 05 Sep 2025 | Option execute | 74,000 | - | - |
| KUMAR NEIL | Officer | 04 Sep 2025 | Automatic sell (-) | 40,000 | 51.83 | 2,073,200 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |